The Life Sciences team advised Verseau Therapeutics, Inc. on its launch and $50 million financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital.
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. The proceeds from the financing will support advancement of Verseau’s macrophage checkpoint modulator (MCM) programs to the clinic.
Goodwin advised Verseau on its strategic collaboration with 3SBio, a fully-integrated biotechnology company in China with market-leading biopharmaceutical franchises. Under the agreement, announced in February 2019, 3SBio will receive an exclusive license to develop and commercialize a select number of MCM antibodies for all human oncology indications in Greater China, including mainland China, Taiwan, Hong Kong and Macau. Verseau retains all other global rights.